The epidemiology of hidradenitis suppurativa (HS) is shifting, with rising global incidence linked to lifestyle changes, hormonal factors, and aging populations. Understanding these trends is critical for stakeholders to anticipate market demand and allocate resources effectively. HS, once considered rare, now affects millions, with its prevalence increasing by 20% since 2018 (World Health Organization, 2024), underscoring the urgency of addressing this growing health challenge.

Risk factors include obesity (linked to 60% of HS cases), hormonal imbalances (more common in women), and genetic predispositions (family history increases risk by 3x). A 2026 study in BMC Dermatology found that HS incidence correlates with rising obesity rates in urban populations, noting a 25% increase in cases in APAC cities since 2020. Additionally, hormonal therapies (e.g., birth control) and smoking are emerging as contributors, expanding the condition’s demographic reach. To analyze these correlations, the HS Epidemiology Trends section of Market Research Future’s report maps regional incidence rates and risk factor distributions.

Regional disparities exist: Europe and North America report the highest prevalence (2-3% of population), while APAC and Latin America see rising cases due to urbanization. A 2026 survey in Brazil found HS prevalence among women aged 20-40 increased by 15% since 2021, driven by obesity and limited dermatology access. These trends are boosting demand for HS treatments, particularly in regions with expanding patient bases.

Market Research Future projects that HS cases will reach 50 million globally by 2030, up from 35 million in 2023. This growth, coupled with improved diagnosis, will drive market expansion, with demand concentrated in areas experiencing lifestyle and demographic shifts. Addressing epidemiological trends will be key to ensuring the HS market meets patient needs and sustains growth.